Sex: M
Vaccine: COVID19
Symptoms: Blood fibrinogen, Coagulation test, Computerised tomogram thorax, Haemodynamic test, Haemoglobin
Clinical narrative: left-sided pulmonary emboli involving the left lower lobe with pulmonary infarction; left-sided pulmonary emboli involving the left lower lobe with pulmonary infarction; This is a literature report for the following literature source(s).  A 24-year-old male patient received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: PULMONARY INFARCTION (hospitalization, medically significant, life threatening), PULMONARY EMBOLISM (hospitalization, medically significant, life threatening), outcome "unknown" and all described as "left-sided pulmonary emboli involving the left lower lobe with pulmonary infarction". The patient underwent the following laboratory tests and procedures: Blood fibrinogen: elevated; Coagulation test: Negative; Computerised tomogram thorax: left-sided pulmonary emboli, notes: pulmonary infarction; Haemodynamic test: stable; Haemoglobin: was stable, notes: throughout the hospital course; Labs: were stable; Physical examination: reduced breath sounds, notes: n the left lower lobe. Therapeutic measures were taken as a result of pulmonary infarction, pulmonary embolism: apixaban (ELIQUIS)  Course of the event. A 24 year old male with no significant past medical history presented to the emergency department due to shortness of breath, hemoptysis and chest pain. He denied any family history or personal history of clotting disorders. He received the mRNA COVID-19 Pfizer vaccine 5 days prior to symptom onset. He describes it as constant sharp pain with varying intensity that he rates a 6/10 and can reach a 10/10 pain exacerbated with lying flat and deep breathing. He also states he has been coughing up a teaspoon amount of blood with this chest pain. Physical examination revealed reduced breath sounds in the left lower lobe. Patient was hemodynamically stable. Lab were stable and hemoglobin was stable throughout the hospital course. Fibrinogen was elevated and hypercoagulable work-up was negative. CTA of chest was performed and revealed left-sided pulmonary emboli involving the left lower lobe with pulmonary infarction. Therefore, he was managed by Eliquis. According to the Authors this case is a demonstration of a rare occurrence of isolated PE with no evidence of DVT in such close proximity to receiving the mRNA COVID-19 Pfizer vaccination; Sender's Comments: Based on available information, the causal association between the event Pulmonary infarction, Pulmonary embolism and suspect drug BNT162b2 cannot be completely excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to RAs, Ethics Committees, and Investigators, as appropriate.